Correlation Between Neuropace and Trinity Biotech

Can any of the company-specific risk be diversified away by investing in both Neuropace and Trinity Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neuropace and Trinity Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neuropace and Trinity Biotech plc, you can compare the effects of market volatilities on Neuropace and Trinity Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neuropace with a short position of Trinity Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neuropace and Trinity Biotech.

Diversification Opportunities for Neuropace and Trinity Biotech

-0.22

Correlation Coefficient

Neuropace  Trinity Biotech

Very good diversification

The 3 months correlation between Neuropace and Trinity is -0.22. Overlapping area represents the amount of risk that can be diversified away by holding Neuropace and Trinity Biotech plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Trinity Biotech plc and Neuropace is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neuropace are associated (or correlated) with Trinity Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Trinity Biotech plc has no effect on the direction of Neuropace i.e., Neuropace and Trinity Biotech go up and down completely randomly.

Pair Corralation between Neuropace and Trinity Biotech

Given the investment horizon of 90 days Neuropace is expected to generate 0.73 times more return on investment than Trinity Biotech. However, Neuropace is 1.37 times less risky than Trinity Biotech. It trades about 0.07 of its potential returns per unit of risk. Trinity Biotech plc is currently generating about -0.02 per unit of risk. If you would invest  340.00  in Neuropace on December 4, 2024 and sell it today you would earn a total of  841.00  from holding Neuropace or generate 247.35% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Neuropace  vs.  Trinity Biotech plc

Neuropace

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Neuropace are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady fundamental indicators, Neuropace may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Trinity Biotech plc

Risk-Adjusted Performance

Very Weak

Over the last 90 days Trinity Biotech plc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong forward indicators, Trinity Biotech is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Neuropace and Trinity Biotech

The main advantage of trading using opposite Neuropace and Trinity Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neuropace position performs unexpectedly, Trinity Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Trinity Biotech will offset losses from the drop in Trinity Biotech's long position.

The idea behind Neuropace and Trinity Biotech plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.